1329 |
Optical Coherence Tomography During PCI: A Research Tool or a Valued Clinical Asset? |
Akiko Maehara |
May. 11. 12 |
1328 |
Transcatheter Renal Denervation for Refractory Hypertension: Current Understanding and Future Projections |
Horst Sievert |
May. 11. 12 |
1327 |
Drug-coated Balloon Technologies II: Clinical Outcomes and Recommended Applications |
William A. Gray |
May. 11. 12 |
1326 |
Drug-coated Balloon Technologies I: Technical Considerations and Controversies |
Juan F. Granada |
May. 11. 12 |
1325 |
Complications After TAVR: Frequency and Clinical Importance |
Martin Bert Leon |
May. 11. 12 |
1324 |
A "Recipe" for Optimizing TAVR Success: Procedural Tips and Tricks |
Corrado Tamburino |
May. 11. 12 |
1323 |
Case Selection for TAVR: Beyond the High-risk Patient |
Eberhard Grube |
May. 11. 12 |
1322 |
Surveying the Landscape of New Anti-platelet Agents: A Practical User¡¯s Guide |
Roxana Mehran |
May. 11. 12 |
1321 |
The Use, Abuse and Value of Platelet Reactivity Testing During Complex PCI |
Sorin Brener |
May. 11. 12 |
1320 |
What¡¯s Known and Unknown about LM PCI: Transitioning from SYNTAX to EXCEL |
Gregg W. Stone |
May. 11. 12 |